Health CarePharmaceuticals & Biotechnology
  • Price (IDR)1,710.00
  • Today's Change0.00 / 0.00%
  • Shares traded559.50k
  • 1 Year change2.09%
  • Beta1.1718
Data delayed at least 10 minutes, as of Jul 26 2017 03:30 BST.
More ▼

Forecasts data is unavailable for this security.

Consensus recommendation

As of Jul 21, 2017, the consensus forecast amongst 15 polled investment analysts covering Kalbe Farma Tbk PT advises that the company will outperform the market. This has been the consensus forecast since the sentiment of investment analysts improved on Apr 11, 2017. The previous consensus forecast advised investors to hold their position in Kalbe Farma Tbk PT.
  • 1yr ago
  • 3M ago
  • 2M ago
  • 1M ago
  • Latest
Select bar for recommendation details.

Share price forecast

The 16 analysts offering 12 month price targets for Kalbe Farma Tbk PT have a median target of 1,750.00, with a high estimate of 2,200.00 and a low estimate of 1,400.00. The median estimate represents a 2.34% increase from the last price of 1,710.00.


In 2016, Kalbe Farma Tbk PT reported a dividend of 22.00 IDR, which represents a 15.79% increase over last year. The 12 analysts covering the company expect dividends of 26.08 IDR for the upcoming fiscal year, an increase of 18.55%.
Div growth (TTM)15.79%
More ▼

Earnings history & estimates

On Apr 28, 2017, Kalbe Farma Tbk PT reported 1st quarter 2017 earnings of 12.55 per share. This result under-performed the 13.43 expectation of the one analyst following the company but exceeded last year's 1st quarter results by 4.41%.
The next earnings announcement is expected on Jul 27, 2017.
Average growth rate+4.07%
Kalbe Farma Tbk PT reported annual 2016 earnings of 49.06 per share on Mar 31, 2017.
Average growth rate+7.51%
More ▼

Revenue history & estimates

PT Kalbe Farma Tbk. had 1st quarter 2017 revenues of 4.90bn. This missed the 4.97bn estimate of the one analyst following the company. This was 7.66% above the prior year's 1st quarter results.
Average growth rate+2.00%
PT Kalbe Farma Tbk. had revenues for the full year 2016 of 19.37bn. This was 8.31% above the prior year's results.
Average growth rate+9.30%
More ▼
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.